Biliary Drainage Plus HAIC in Locally Advanced pCCA

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

When a patient is not eligible for surgery, chemotherapy with gemcitabine and cisplatin can be considered in advanced biliary tract cancers. However, in the Advanced Biliary Cancer, or ABC-2, trial in patients with pCCA, the efficacy of this regimen was not significantly higher than that of gemcitabine alone. Therefore, an optimal chemotherapeutic regimen has not been established for this subtype of cholangiocarcinoma. Currently, biliary drainage and stent placement remains to be the main palliative treatment choice, and the life expectancy is only 4-6 months. Previous single center prospective phase 2 trial showed that HAI with oxaliplatin and 5-fluorouracil was an encouraging treatment choice for advanced PCC due to its high tumor control, survival benefit, and low toxicity. So the multicenter prospective controlled trial was designed to explore and confirm the survival benefit of biliary drainage plus hepatic arterial infusion of oxaliplatin and 5-fluorouracil compared with biliary drainage plus best support care treatment in locally advanced pCCA patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University
• Treatments: Fluorouracil; Oxaliplatin

Criteria

Inclusion Criteria:

1. Locally advanced perihilar cholangiocarcinoma proved by histology or cytology.

2. Locally advanced unresectable perihilar cholangiocarcinoma, decided by hepatobiliary doctor and radiologist.

3. Age from 18 years old to 75 years old.

4. The performance of Eastern Cooperative Oncology Group (ECOG) <2

5. Child-Pugh A or Child-Pugh B (≤ grade 7).

6. Expectant survival time ≥ 3 months.

7. Baseline blood count test and blood biochemical must meet following criteria:

1. Hemoglobin ≥ 90 g/L;

2. Absolute neutrophil count ≥ 1.5×10^9/L;

3. Blood platelet count ≥ 100×10^9/L;

4. Serum creatinine ≤ 1.5 times of ULN;

5. Albumin ≥ 30 g/L

8. Patients sign informed consent.

Exclusion Criteria:

1. Allergic to contrast agent.

2. Pregnant or lactational.

3. Allergic to 5-fluorouracil, or have metabolic disorder of 5-fluorouracil.

4. Previous systematic chemotherapy or radiotherapy.

5. Patients with complications such as bile leakage and bleeding after PTCD

6. N2 lymphatic metastasis, extrahepatic metastasis, or coinstantaneous a lot of malignant hydrothorax or ascites.

7. History of organ transplantation.

8. Coinstantaneous infection and need anti-infection therapy.

9. Coinstantaneous peripheral nervous system disorder or with history of obvious mental disorder and central nervous system disorder.

10. Diagnosed other kinds of malignant within 5 years, except for non-melanoma skin cancer and carcinoma in situ of cervix.

11. Without legal capacity.

12. Uncorrectable coagulation disorder.

13. Obvious abnormal in ECG or obvious clinical symptoms of heartdisease, like congestive heart failure (CHF), coronary heart disease with obvious clinical symptoms, unmanageable arrhythmia and hypertension.

14. Severe liver disease (like cirrhosis), renal disease, respiratory disease,unmanageable diabetes or other kinds of systematic disease.